US pharma giant's investment in S'pore will reinforce drug supply chain, boost new vaccine production

The syringe and vial-packing section in MSD’s current manufacturing facility in Tuas. ST PHOTO: GAVIN FOO
Gift this subscriber-only story to your friends and family

SINGAPORE - MSD's new investment here will put Singapore at the heart of its revamped global supply chain from where the US drugmaker will produce and distribute its latest innovative medicine and vaccines.

The new manufacturing facilities and investments in digitalisation and automation will enhance distribution capabilities, lowering the risk of supply disruptions, said Mr David Peacock, the Asia-Pacific president of MSD - a firm known as Merck & Co in the United States and Canada.

Already a subscriber? 

Read the full story and more at $9.90/month

Get exclusive reports and insights with more than 500 subscriber-only articles every month

Unlock these benefits

  • All subscriber-only content on ST app and straitstimes.com

  • Easy access any time via ST app on 1 mobile device

  • E-paper with 2-week archive so you won't miss out on content that matters to you

Follow ST on LinkedIn and stay updated on the latest career news, insights and more.